Section Review: Biologicals & Immunologicals: New insights into the pathogenesis and treatment of cytomegalovirus

References

• FORMAN SJ, ZAIA JA: Treatment and prevention of cytomegalovirus pneumonia after bone marrow trans-plantation: where do we stand? Blood (1994) 83:2392–2398.
   PubMed Web of Science ®Google Scholar
• SING GK, RUSCETTI FW: The role of human cytomega-lovirus in haematological diseases. Balliere's Clinical Haematology (1995):149–163.
   PubMedGoogle Scholar
• BRON D, LAGNEAUX L, DELFORGE A, OTTE C, SNOECK R, STRYCKMANS P: Prevention of CMV-induced myelosup-pression by anti-CMV antibodies: an in vitro modeL Exp. Hematol. (1991) 19:132–135.
   Web of Science ®Google Scholar
• LAGNEAUX L, DELFORGE A, SNOECK R, DE CLERCQ E,STRYCKMANS P, BRON D: Perturbation of cytokine pro-duction by bone marrow stromal cells after cytomega-lovirus infection. In: Multidisciplinary Approach to Understanding Cytomegalovirus Disease. Michelson S, Plot-kin SA (Eds.), Elsevier Science Publishers, Amsterdam (1993):111–116.
   Google Scholar
• LAGNEAUX L, DELFORGE A, SNOECK R, STRYCKMANS P, BRON D: Decreased production of cytokines after cy-tomegalovirus infection of marrow-derived stromal cells. Exp. Hematol. (1994) 22:26–30.
   PubMed Web of Science ®Google Scholar
• LAGNEAUX L, DELFORGE A, SNOECK R, BOSMANS E, MOREAU JF, TAUPIN JL, DE CLERCQ E, STRYCKMANS P, BRON D: Human cytomegalovirus increases constitu-tive production of interleukin-6 and leukemia inhibi-tory factor by bone marrow stromal cells. Blood (1996) 87:59–66.
   PubMed Web of Science ®Google Scholar
• QUINNAN GV, KIRMANI N, ROOK AH, MANISCHEWITZ JF, seJACKSON L, MORESCHI G, SANTOS GW, SARAL R, BURNSWH: Cytotoxic T-cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non T-lymphocyte cytotoxic responses correlate with recovery from cy-tomegalovirus in bone marrow recipients. New Engl. J. Med. (1982) 307:7–11.
   PubMed Web of Science ®Google Scholar
• REUSSER P, RIDDELL S, MEYERS J, GREENBERG P: Cyto- •toxic T-lyraphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pat-tern of recovery and correlation with cytomegalovirus Infection and disease. Blood (1991) 78:1373–1380.
   PubMed Web of Science ®Google Scholar
• LJUNGMAN P, ASCHAN J, AZINGE JN, BRANDT L, EHRNST A, HAMMARSTROM V, KLAESSON S, LINDE A, LONNQVIST B, RINGDEN 0, GAHRTON G: Cytomegalovirus viraemia and specific T-helper cell response as predictors of disease after allogeneic marrow transplantation. Br. J. Haematol. (1993) 83:118–124.
   PubMed Web of Science ®Google Scholar
• LI CR, GREENBERG PD, GILBERT MJ, GOODRICH JM, RIDDELL SR: Recovery of HLA-restricted cytomega-lovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood (1994) 83:1971–1979.
   PubMed Web of Science ®Google Scholar
• FRIES BC, KHAIRA D, PEPE MS, TOROK-STORB B: Declin- ing lymphocyte counts following cytomegalovirus (CMV) infection are associated with fatal CMV disease in bone marrow transplant recipients. Exp. Hematol. (1991) 21:1387–1392.
   Web of Science ®Google Scholar
• EINSELE H, EHNINGER G, STEIDLE, FISCHER I, BIHLER S,GERNETH F, VALLBRACHT A, SCHMIDT H, WAILER HD, MULLER CA: Lymphocytopenia as an unfavourable prog-nostic factor in patients with cytomegalovirus infection after bone marrow transplantation. Blood (1 99 3) 82:1672-1678.
   Google Scholar
• GROB JP, GRUNDY JE, PRENTICE HG, GRIFFITHS PD,HOFFBRAND AV, HUGHES MD, TATE T, WIMPERIS JZ, BRENNER MK: Immune donors can protect marrow-transplant recipients from severe cytomegalovirus in-fections. Lancet (1987) 1:774.
   PubMed Web of Science ®Google Scholar
• BOLAND GJ, VLIEGER A, VERVERS C, DE GAST GC: Evi-dence for transfer of cellular and humoral immunity to cytomegalovirus from donor to recipient in allogeneic bone marrow transplantation. Clin. Exp. Immunol. (1991) 88:506–511.
   Web of Science ®Google Scholar
• ROY DM, BRENNER MK, COOK D, DUNCAN RI, GRIFFITHS PD, GRUNDY JE: Transfer of humoral immunity against cytomegalovirus proteins following transplantation of T-cell-depleted allogeneic bone marrow from seroposi-tive donors. J. Med. Virol. (1993) 41:150–158.
   PubMed Web of Science ®Google Scholar
• MEYERS JD, FLOURNOY N, THOMAS ED: Risk factors for cytomegalovirus infection after human marrow trans-plantation. J. Infect. Dis. (1986) 153:478.
   PubMed Web of Science ®Google Scholar
• MILLER W, FLYNN P, MCCULLOUGH J, BALFOUR HI-I, Jr., GOLDMAN A, HAAKE R, MCGLAVE P, RAMSAY N, KERSEY J: Cytomegalovirus infection after bone marrow trans-plantation: an association with acute graft-versus-host disease. Blood (1986) 67:1162.
   Google Scholar
• MEYERS JD, LJUNGMAN P, FISHER LD: Cytomegalovirusexcretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomega-lovirus viraemia. J. Infect. Dis. (1990) 162:373–378.
   PubMed Web of Science ®Google Scholar
• BOECKH M, BOWDEN RA, GOODRICH JM, PETTINGER M, MEYERS JD: Cytomegalovirus antigen detection in pe-ripheral blood leukocytes after allogenek marrow transplantation. Blood (1992) 80:1358–1364.
   PubMed Web of Science ®Google Scholar
• EHRNST A, BARKHOLT L, BRATISTROM C, CZAJKOWSKI J, TEODOSIU 0, TOLLEMAR J, LJUNGMAN P: Detection of CMV-matrix pp65 antigen leukocytes by inununofluo-rescence as a marker of CMV disease. J. Med. ViroL (1993) 39:118–124.
   PubMed Web of Science ®Google Scholar
• SCHMIDT C, OETTLE H, WILBORN F, JESSEN J, TIMM H, SCHWERDFEGER R, OERTEL J, S1EGERT W: Demonstra-tion of cytomegalovirus after bone marrow transplan-tation by polymerase chain reaction, virus culture and antigen detection in huffy coat leukocytes. Bone Marrow Transplant. (1994) 1 3:71–75.
   Google Scholar
• WOLF DG, SPECTOR SA: Early diagnosis of human cy-tomegalovirus disease in transplant recipients by DNA amplification in plasma. Transplantation (1993) 36:330–334
   Google Scholar
• CINQUE P, VAGO L, BRYTT1NG M, CASTAGNA A, ACCOR-DINI A, SUNDQVIST VA, ZANCHETTA N, MONFORTE AD, WAHREN B, LAZZARIN A: Cytomegalovirus infection of the central nervous system in patients with AIDS: diag-nosis by DNA amplification from cerebrospinal fluid. J. Infect. Dis. (1992) 166:1408–1411.
   PubMed Web of Science ®Google Scholar
• CLIFFORD D, BULLER R, MOHAMMED S, ROBISON L, STORCH G: Use of the polymerase chain reaction to demonstrate cytomegalovirus DNA in CSF of patients with human immunodeficiency virus infection. Neurol-ogy (1993) 43:75–79.
   PubMed Web of Science ®Google Scholar
• ERIKSSON BM, BRYTTING M, ZWEYGBERG WB, HILLER-DAL G, OLDING SE, LINDE A: Diagnosis of cytomega-lovirus in bronchoalveolar lavage by polymerase chain reaction in comparison with virus isolation and detec-tion of viral antigen. Scand. J. Infect. Dis. (1993) 25:421–427.
   PubMed Web of Science ®Google Scholar
• CATHOMAS G, MORRIS P, PEKLE K, CUNNINGHAM I, EMANUEL D: Rapid diagnosis of cytomegalovirus pneu-monia in marrow transplant recipients by bron-choalveolar lavage using the polymerase chain reaction, virus culture and the direct immunostaining of alveolar cells. Blood (1993) 81:1901–1914.
   Google Scholar
• EINSELE H, EHNINGER G, STEIDLE M, VALBRACHT A, MULLER M, SCHMIDT H, SAAL JG, WALLER HD, MULLER CA: Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease. Lancet (1991) 338:1170–1173.
   PubMed Web of Science ®Google Scholar
• WEBSTER A, BLIZZARD B, PILLAY D, PRENTICE HG, POTHECARY K, GRIFFITHS PD: Value of routine surveil-lance cultures for detection of CMV pneumonitis follow-ing bone marrow transplantation. Bone Marrow Transplant. (1993) 12:477–481.
   PubMed Web of Science ®Google Scholar
• BUSCH A, KIRCHINER H, DENNIN R, HOYER J, PRICER L, STEINHOFF J, SACK K, BEIN G: The long persistence of CMV-DNA in the blood of renal transplant patients after recovery from CMV infection. Transplantation (1993) 56:108–113.
   PubMed Web of Science ®Google Scholar
• EINSELE H, EHNINGER G, HEBART H, WITTOWSKI K, •SCHULER U, JAHN G, MACKES P, HERTER M, KLINGEBIELT, LOFFLER J, WAGNER S, MULLER CA: Polymerase chain reaction monitoring reduces the incidence of cy-tomegalovirus disease and the duration and side-effects of antiviral therapy after bone marrow transplantation. Blood (1995) 86:2815–2820.
   PubMed Web of Science ®Google Scholar
• BOWDEN RA, SAYERS M, FLOURNOY N, NEHON B, BANAJI M, THOMAS ED, MEYERS J: Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow trans-plantation. New Eng. J. Med. (1986) 314:1006.
   PubMed Web of Science ®Google Scholar
• MILLER WJ, MCCULLOUGH J, BALFOUR HHJR, HAAKE RJ, RAMSAY NKC, GOLDMAN A, BOWDAN R, KERSEY J: Pre-vention of cytomegalovirus infection following bone marrow transplantation: a randomized trial of blood product screening. Bone Marrow Transplant. (1991) 7:227–232.
   PubMed Web of Science ®Google Scholar
• GILBERT GL, HAYES K, HUDSON IL, JAMES J: The NeonatalCMV Infection Study Group: prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leukocytes. Lancet (1989) 1:1228–1282.
   PubMed Web of Science ®Google Scholar
• SMITH K, COBAIN T, DUNSTAN R: Removal of cytomega-lovirus-DNA from donor blood by filtration. Br. J. Hae-matol. (1993) 30:49–30.
   Google Scholar
• BOWDEN RA, SLIGHTER SJ, SAYERS MH, MORI M, CAYS MJ, MEYERS JD: Use of leukocyte-depleted platelets and cytomegalovirus seronegative red blood cells for pre-vention of primary cytomegalovirus infection after marrow transplant. Blood (1991) 78:246–251.
   PubMed Web of Science ®Google Scholar
• MEYERS JD, REED EC, SHEEP DH, THORNQUIST M, DAN- DLIKER PS, VICARY CA, FLOURNOY N, KIRK LE, KERSEY JH, THOMAS ED, BALFOUR HH, Jr.: Acyclovir for preven-tion of cytomegalovirus infection and disease after allogeneic marrow transplantation. N. Eng.J. Med. (1988) 318:70–75.
   Google Scholar
• LJUNGMAN P, PRENTICE G, GLUCKMAN E, POWLES R, MLLPIED N, RANADA J, MANDELLI F, FOR THE EUROPEAN ACYCLOVIR IN CMV PROPHYLAXIS GROUP: The effect of Intravenous acyclovir followed by oral acyclovir on CMV infections following bone marrow transplanta-tion. A randomised double-blind controlled trial. In: Multidisciplinary Approach to Understanding Cytomega-lovirus Disease. Proceedings of the Fourth International Cy-tomegalovirus Workshop. Michelson S, Plotkin SA (Eds.), Excerpts Medica, New York, NY (1993).
   Google Scholar
• PRENTICE HG, GLUCKMAN E, POWLES RI, LJUNGMAN P, MILPIED N, FERNANDEZ RJ, MANDELLI F, KHO P, KEN-NEDY L, BELL AR: Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet (1994) 343:749–753.
   PubMed Web of Science ®Google Scholar
• GOODRICH J, BOWDEN R, FISHER L, KELLER C, SCHOCH G, MEYERS J: Gancklovir prophylaxis to prevent cy-tomegalovirus disease after allogeneic marrow trans-plant. Ann. Intern. Med. (1993) 118:173–178.
   PubMed Web of Science ®Google Scholar
• WINSTON D, HO W, BARTONI K, DU MOND C, EBELING D, BUHLES W, CHAMPLIN R: Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann. Intern. Med. (1993) 118:179–184.
   PubMed Web of Science ®Google Scholar
• ATKINSON K, DOWNS K, GOLENIA M, BIGGS J, MARSHALLG, DODDS A, CONCANNON A: Prophylactic use of gan-ciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection. Br. J. Haematol. (1991) 79:57.
   PubMed Web of Science ®Google Scholar
• YAU JC, DIMOPOULOS MA, HUAN SD, TARRAND JJ, SPENCER V, SPITZER G, MENEGHETTI CM, WALLERSTEIN RO, ANDERSSON BS, LE MAISTRE CF: Prophylaxis of cytomegalovirus infection with ganciclovir in allo-geneic marrow transplantation. Eur. J. Haematol. (1991) 371–376.
   PubMed Web of Science ®Google Scholar
• VON BUELTZINGSLOEWEN A, BORDIGONI P, WITZ F, BENE MC, SCHMITT C, LACOUR B, SOMMELET D: Prophy-lactic use of ganciclovir for allogeneic bone marrow transplant recipients. Bone Marrow Transplant. (1992) 12:197–201.
   Web of Science ®Google Scholar
• REUSSER P, GAMBERTOGLIO J, LTU.FBY K, MEYERS J: Phase I-II trial of foscarnet for prevention of cytomega-lovirus infection in autologous and allogeneic marrow transplant recipients. J. Infect. Dis. (1992) 166:473–479.
   Google Scholar
• WINSTON DJ, HO WG, UN CH, BARTONI K, BUDINGER MD, GALE RP, CHAMPLIN RE: Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow trans-plantation. Ann. Intern. Med. (1987) 106:12–18.
   PubMed Web of Science ®Google Scholar
• SULLIVAN KM, KOPECKY KJ, JOCOM J, FISHER L, BUCKNER CD, MEYERS JD, COUNTS FW, BOWDEN RA, PETERSEN FB, WITHERSPOON RP, BUDINGER MD, SCHWARTZ RS, AP-PELBAUM FR, CLEFT RA, HANSEN JA, SANDERS JE, THOMAS ED, STORB R: Inununomodulatory and anti-microbial efficacy of intravenous immunoglobulin in bone mar-row transplantation. New Engl.J. Med. (1990) 323:705–711.
   PubMed Web of Science ®Google Scholar
• BASS EB, POWE NR, GRAZIANO SL, GOODMAN SN, GRIF-FITHS RI, KICKLER TS, WINGARD JR: Efficacy of intrave-nous immune globulin in preventing complications of bone marrow transplantation: a meta-analysis. Bone Marrow Transplant. (193) 12:179–183.
   Google Scholar
• MESSORI A, RAMPAZZO R, SCROCCARO G, MARTINI N: Efficacy of hyperinamune anti-cytomegalovirus immu-noglobulins for the prevention of cytomegalovirus in- fection in recipients of allogeneic bone marrow trans-plantation: a meta-analysis. Bone Marrow Transplant. (1994) 13:163–168.
   PubMed Web of Science ®Google Scholar
• BOWDEN RA, FISHER LK, ROGERS K, CAYS M, MEYERS JD:Cytomegalovkus (CMV)-specific intravenous immuno-globulin for the prevention of primary CMV infection and disease after marrow transplant. J. Infect. Dis. (1991) 164–483.
   Google Scholar
• GUGLIELMO BJ, WONG-BERINGER A, LINKER CA: Im-mune globulin therapy in allogeneic bone marrow transplant: a critical review. Bone Marrow Transplant. (1994) 13:499–510.
   PubMed Web of Science ®Google Scholar
• SCHMIDT G, HORAK, DA, NILAND JC, DUNCAN SR, FOR- MAN SJ, ZAIA JA: A randomized controlled trial of prophylactic ganciclovir for cytomegalovirus pulmo-nary infection in recipients of allogeneic bone marrow transplants. N. Engl. J. Med. (1991) 324:1057–1059.
   PubMedGoogle Scholar
• GOODRICH JM, MORI M, GLEAVES CA, GLEAVES MS, DUMOND C, CAYS M, EBELING DF, BUHLES WC, DEAR-MOND B, MEYERS JD: Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. New Eng. J. Med. (1991) 325:1601–1607.
   PubMed Web of Science ®Google Scholar
• BRATANOW MC, ASH RC, TURNER PA, SMITH R, HAASLERG, CHITAMBAR C, HANSEN R, CASPER J: Successful treat-ment of serious cytomegalovirus disease with 9-(1,3-di-hydroxy-2-propoxymethyl)-guanine and intravenous immunoglobulin in bone marrow transplant patients. Exp. Hematol. (1987) 15:541–546.
   Web of Science ®Google Scholar
• REED EC, BOWDEN RA, DANDLIKER PS, LLLLEBY RE, MEYERS JD: Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus im-munoglobulin in patients with bone marrow trans-plants. Ann. Intern. Med. (1988) 109:783–792.
   PubMed Web of Science ®Google Scholar
• EMANUEL D, CUNNINGHAM I, JULES-ELYSEE K, BROCHSTEIN JA, KERNAN NA, LAVER J, STOVER D, WHITE DA, FELS A, POLSKY B, CASTRO-MALASPINA H, PEPPARD JR, BARTUS P, HAMMERLING U, O'REILLY RJ: Cytomega-lovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganci-dovir and high-dose intravenous immune globulin. Ann. Intern. Med. (1988) 109:777–781.
   PubMed Web of Science ®Google Scholar
• SCHMIDT G, KOVACS A, ZAIA JA, HORAK DA, BLUME KG, NADEMANEE AP, O'DONNELL MR, SNYDER DS, FORMAN SJ: Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipi-ents. Transplantation (1988) 46:905–909.
   PubMed Web of Science ®Google Scholar
• LJUNGMAN P, ENGELHARD D, LINK H, &RON P, BRANDT L, BRUNET S, CORDONNEIR C, DEBUSSCHER L, DE LAURENZI A, KOLB HJ et al.: Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of Euro-pean Bone Marrow Transplant Group. Clin. Infect. Dis. (1992) 14:831–835.
   Google Scholar
• ENRIGHT H, HAAKE R, WEISDORF D, RAMSAY N, MCGLAVE P, KERSEY J, THOMAS W, MCKENZIE D, MITI.FR W: Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy. Transplantation (1993) 55:1339–1346.
   Google Scholar
• POLIS MA: Design of a randomised controlled trial offoscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome. Am. J. Med. (1992) SuppL 2A:22S-25S. •
   Google Scholar
• DE CLERCQ E: Trends in the development of new antivi-ral agents for the chemotherapy on infection caused by herpes viruses and retroviruses. Med. Virol. (1995) 5:149–164.
   Google Scholar
• CHOU S, GUENTZEL S, MICHELS KR, MINER RC, DREW WL: Frequency of UL97 mutations related to ganciclovir resistance in clinical CMV isolates. The Fifth International Cytomegalovirus Conference 'A Multidisciplinaty Approach Towards Controlling Cytomegalovirus Disease'. Stockholm, Sweden (1995):82A.
   Google Scholar
• SPECTOR AS, MCKINLEY G, DREW, WL, STEMPLEN MJ FORTHE SYNTEX GANCICLOVIR STUDY GROUP: A random-ized, double-blind study of the efficacy and safety or oral ganciclovir for the prevention of cytomegalovirus disease in HIV-infected persons. The Fifth International Cytomegalovirus Conference 'A Multidisciplinary Approach Toward Controlling Cytomegalovirus Disease'. Stockholm, Sweden (1995):80A.
   Google Scholar
• HO HT, WOODS KL, BRONSON JJ, DEBOECK H, MARTINJC, HITCHCOCK MJM: Intracellular metabolism of the antiherpes agent (S)443-hydroxy-2-(phosphonyl-methoxy)propylicytosine. Mol. Pharmacol. (1992) 41:197–202.
   PubMed Web of Science ®Google Scholar
• DREW WL, LALEZARI JP, GLUTZER E: The safety, pharma-cokinetics, and anti-CMV activity of weekly HPMPC in HIV positive patients excreting CMV. In: Multidisciplinary Approach to Understanding Cytomegalovirus Disease. Michelson S, Plotkin SA (Eds.), Excerpta Medica, Elsevier, Amsterdam (1993):287–292.
   Google Scholar
• LALEZARI J, STAGG R, KUPPERMAN B et al.: A Phase 11/11I randomized study of immediate versus deferred intra-venous (iv) cidofovir (CDV, HPMPC) for the treatment of CMV retinitis in AIDS patients. J. Infect. Dis. (1995) 171:788–796.
   PubMed Web of Science ®Google Scholar
• KIRSCH IS, AREVALO JF, DE CLERCQ E, CHAVEZ DE LA PAZ E, MUNGUIA D, GARCIA R, FREEMAN WR: Phase I/I1 study of intravitreal Cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired Immunodeficiency syndrome. Am. J. ophtb. (1995) 119:466–476.
   PubMed Web of Science ®Google Scholar
• NISHIYAMA Y, YAMAMOTO N, TAKAHASHI N, SHIMADA N: Selective inhibition of human cytomegalovirus rep-lication by a novelnucleoside, oxetanocin. J. Antimicrob. Agents Cbemother. (1988) 32:1053–1056.
   PubMed Web of Science ®Google Scholar
• WALTER EA, GREENBERG PD, GILBERT MJ, FINCH RJ, •WATANABE KS, THOMAS ED, RIDDELL SR: Reconstitutionof cellular immunity against cytomegalovirus in recipi-ents of allogeneic bone marrow by transfer of T-cell clones from the donor. New Engl. J. Med. (1995) 333:1038–1044.
   PubMed Web of Science ®Google Scholar
• RIDDELL SR, WATANABE KS, GOODRICH JM, LI CR, AGHA ME, GREENBERG PD: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones. Science (1992) 257:238–241.
   PubMed Web of Science ®Google Scholar
• PLOTKIN SA. Cytomegalovirus vaccine development - past and present. Transplant Proc. (1991) 23:85–89.
   PubMed Web of Science ®Google Scholar
• GONCZOL E, IANACONE J, HOW, STARR S, MEIGNIER B, PLOTKIN S: The isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers. Vaccine (1991) 8:130–135.
   Web of Science ®Google Scholar
• LIU Y-NC, ICARI B, GEHRZ RC: Human immune responses to major human cytomegalovirus glycoprotein com-plexes. J. Virol. (1988) 62:1066–1071.
   PubMed Web of Science ®Google Scholar
• PASS RE, DLTLIEGE AM, BOPPANA SB, BRITT WJ, GRANOFF DM, SEKULOVITCH R, BURKE RL: A Phase! trial of Biocine CMV g,B vaccine in seronegative adults. The Filth Interna-tional Cytomegalovirus Conference 'A Multidisciplinary Ap-proach Towards Controlling Cytomegalovirus Disease'. Stockholm, Sweden (1995):80A.
   Google Scholar
• LAFEMINA RE, PRAMANIK B, VELOSKI C, LONG W, LEGROS K, WOLANSKI B, HAZUDA DJ: Inhibition of the human cytomegalovirus U180 mature protease by small pep-tides. The Fifth International Cytomegalovirus Conference 'A Multidisciplinaly Approach Towards Controlling Cytomega-lovirus Disease'. Stockholm, Sweden (1995):81A.
   Google Scholar